SCHEMBL6024316

SCHEMBL6024316

Cc1cc[n+]([O-])c2cc(N)c(S(=O)(=O)O)cc12

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.35
HSD17B10 Q99714 3/20 0.35
CASP6 P55212 2/20 0.35
CYP2C9 P11712 2/20 0.35
CYP2C19 P33261 2/20 0.35
TTR P02766 1/20 0.34
SENP2 Q9HC62 5/20 0.34
SUMO2 P61956 4/20 0.34
SUMO1 P63165 4/20 0.34
SENP7 Q9BQF6 4/20 0.34
SENP1 Q9P0U3 4/20 0.34
SENP3 Q9H4L4 3/20 0.34
TP53 P04637 2/20 0.32
BRD4 O60885 1/20 0.32
CREBBP Q92793 1/20 0.32
KDM4E B2RXH2 4/20 0.31
CTDSP1 Q9GZU7 1/20 0.31
MAPT P10636 3/20 0.31
MEN1 O00255 2/20 0.31
RECQL P46063 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6023304 0.74 GAA (0.35) TP53GAACYP3A4TSHR
SCHEMBL6023392 0.72 MEN1 (0.33) ALDH1A1HSD17B10CYP2C9CYP2C19SENP2
SCHEMBL6938187 0.69 CYP3A4 (0.44) ALDH1A1HSD17B10CASP6CYP2C9CYP2C19
SCHEMBL4429911 0.68 ALDH1A1 (0.39) ALDH1A1HSD17B10TP53KDM4EMAPT
SCHEMBL31697699 0.67 BRD4 (0.49) ALDH1A1HSD17B10CASP6CYP2C9CYP2C19
SCHEMBL428347 0.67 CYP3A4 (0.42) ALDH1A1HSD17B10CASP6CYP2C9CYP2C19
SCHEMBL1755154 0.67 BRD4 (0.49) ALDH1A1HSD17B10CASP6CYP2C9CYP2C19
SCHEMBL7032447 0.67 CYP3A4 (0.48) ALDH1A1HSD17B10CASP6CYP2C9CYP2C19
SCHEMBL1755030 0.67 BRD4 (0.49) ALDH1A1HSD17B10CASP6CYP2C9CYP2C19
SCHEMBL1412987 0.66 TTR (0.46) ALDH1A1HSD17B10CASP6CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7144993-B2 Process for the preparation of 4-methyl-7-aminoquinolones CIBA SPECIALTY CHEMICALS CORP. (US) 2006-12-05 US disclosed
US-20050222397-A1 Process for the preparation of 4-methyl-7-aminoquinolones CIBA SPECIALTY CHEMICALS CORP. 2005-10-06 US disclosed
EP-1453809-A1 PROCESS FOR THE PREPARATION OF 4-METHYL-7-AMINOQUINOLONES Ciba SC Holding AG (CH) 2004-09-08 EP disclosed
WO-2003050089-A1 PROCESS FOR THE PREPARATION OF 4-METHYL-7-AMINOQUINOLONES CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2003-06-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050222397-A1 Process for the preparation of 4-methyl-7-aminoquinolones CBR1, CBR3, MRPL21 ALDH1A1 2050/4885HSD17B10 587/4885CASP6 3697/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.